Vedaprofen

Research use only, not for human use.

Vedaprofen inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM.

Vedaprofen inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM.(In Vitro):Vedaprofen blocks the activity of the E. coli DNA polymerase III β subunit, preventing DNA replication and repair. Vedaprofen inhibits horse serum TxB2 and horse exudate PGE2 with IC50s of 9 ng/mL and 630 ng/mL, respectively. (In Vivo):In beagle dogs, the absorption of Vedaprofen (0.5 mg/kg; oral) was rapid (tmax 0.63 h) and almost complete (bioavailability 86%). The terminal half-lives after intravenous and oral administration, 16.8 and 12.7 h respectively, were of the same order of magnitude. Vedaprofen does not accumulate in plasma.

Vedaprofen inhibits horse serum TxB2 and horse exudate PGE2 with IC50s of 9±5 and 630±148 ng/mL, respectively.Vedaprofen inhibit the E. coli DNA polymerase III β subunit with antibacterial potency.Vedaprofen shows high E. coli SC binding affinity (Ki=131 μM).

Pharmacokinetic parameters of vedaprofen in dogs.

Quadrisol | CERM 10202 | PM 150

Chromatin/Epigenetic

COX

——

——

——

71109-09-6

282.38

C19H22O2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (177.07 mM)

O=C(O)C(C=1C=CC(=C2C=CC=CC21)C3CCCCC3)C

——

(-20℃)

With Ice Pack

≥ 2 years